PDF herunterladen
Thromb Haemost 2022; 122(08): 1288-1295
DOI: 10.1055/a-1707-2130
Coagulation and Fibrinolysis

Coagulation Factor V (F5) is an Estrogen-Responsive Gene in Breast Cancer Cells

Marianne S. Andresen
1   Department of Haematology, Oslo University Hospital, Oslo, Norway
2   Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway
,
Marit Sletten
3   Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
,
Per Morten Sandset 
1   Department of Haematology, Oslo University Hospital, Oslo, Norway
2   Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway
4   Department of Haematology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
,
Nina Iversen
3   Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
,
Benedicte Stavik   *
1   Department of Haematology, Oslo University Hospital, Oslo, Norway
2   Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway
,
Mari Tinholt   *
1   Department of Haematology, Oslo University Hospital, Oslo, Norway
3   Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Most breast cancers express estrogen receptor (ER) where estrogen signaling plays an important role. Cancer contributes to activation of the coagulation system leading to an imbalance in the hemostatic system, and coagulation factor (F) V, which is a key regulator of blood coagulation, has been shown to be increased in breast tumors. Thus, the molecular association between estrogens and FV was explored. Stimulation with 17-β-estradiol (E2) or 17-β-ethinylestradiol (EE2) resulted in a time- and dose-dependent increase in F5 messenger RNA and FV protein in ERα-positive MCF-7 cells. Pretreatment with the ER antagonist fulvestrant or knockdown of ERα prior to stimulation with E2 counteracted this effect. Three ERα-binding half-sites were identified in the promoter region of the F5 gene in silico. Reporter gene analysis showed that all three half-sites were involved in the estrogen-induced gene regulation in vitro, as the effect was abolished only when all half-sites were mutated. High F5 levels in ER-positive breast tumors were associated with increased relapse-free survival of breast cancer patients.

Keywords

estrogen - coagulation factor V (F5) - MCF-7 cells - ER-positive breast tumors - relapse-free survival

Author Contributions

M.S.A. performed experiments, analyzed the data, and wrote the manuscript. M.S. performed experiments and critically revised the manuscript. P.M.S. critically revised the manuscript and provided funding for the study. N.I. conceived the study, performed the bioinformatics on the ERE binding sites and patient material, and critically revised the manuscript. B.S. and M.T. conceived and designed the study, performed experiments, and critically revised the manuscript.


Data Availability

The data generated during the current study are not publicly available but are available from the corresponding author on reasonable request.


* Equal contribution.


Supplementary Material



Publikationsverlauf

Eingereicht: 16. April 2021

Angenommen: 25. November 2021

Accepted Manuscript online:
26. November 2021

Artikel online veröffentlicht:
20. Januar 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013; 11 (02) 223-233
    CrossrefPubMedSuche in Google Scholar
  • 2 Leiva O, Newcomb R, Connors JM, Al-Samkari H. Cancer and thrombosis: new insights to an old problem. J Med Vasc 2020; 45 (6S): S8-S16
    PubMedSuche in Google Scholar
  • 3 Dahlbäck B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol 2016; 38 (Suppl. 01) 4-11
    CrossrefPubMedSuche in Google Scholar
  • 4 Cramer TJ, Gale AJ. The anticoagulant function of coagulation factor V. Thromb Haemost 2012; 107 (01) 15-21
    Thieme ConnectPubMedSuche in Google Scholar
  • 5 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31 (15) 3777-3785
    CrossrefPubMedSuche in Google Scholar
  • 6 Tabibian S, Shiravand Y, Shams M. et al. A comprehensive overview of coagulation factor V and congenital factor V deficiency. Semin Thromb Hemost 2019; 45 (05) 523-543
    Suche in Google Scholar
  • 7 Tinholt M, Stavik B, Tekpli X. et al. Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. OncoImmunology 2020; 9 (01) 1824644
    CrossrefPubMedSuche in Google Scholar
  • 8 Tinholt M, Garred Ø, Borgen E. et al. Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study. J Thromb Haemost 2018; 16 (07) 1347-1356
    CrossrefPubMedSuche in Google Scholar
  • 9 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    Suche in Google Scholar
  • 10 Testa U, Castelli G, Pelosi E. Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments. Med Sci (Basel) 2020; 8 (01) E18
    PubMedSuche in Google Scholar
  • 11 Harbeck N, Penault-Llorca F, Cortes J. et al. Breast cancer. Nat Rev Dis Primers 2019; 5 (01) 66
    CrossrefPubMedSuche in Google Scholar
  • 12 Szymiczek A, Lone A, Akbari MR. Molecular intrinsic versus clinical subtyping in breast cancer: a comprehensive review. Clin Genet 2020; 99 (05) 613-637
    CrossrefPubMedSuche in Google Scholar
  • 13 Hilton HN, Clarke CL, Graham JD. Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol 2018; 466: 2-14
    CrossrefPubMedSuche in Google Scholar
  • 14 Vrtačnik P, Ostanek B, Mencej-Bedrač S, Marc J. The many faces of estrogen signaling. Biochem Med (Zagreb) 2014; 24 (03) 329-342
    CrossrefPubMedSuche in Google Scholar
  • 15 Ayaz G, Yasar P, Olgun CE. et al. Dynamic transcriptional events mediated by estrogen receptor alpha. Front Biosci 2019; 24: 245-276
    CrossrefPubMedSuche in Google Scholar
  • 16 Lipovka Y, Konhilas JP. The complex nature of oestrogen signalling in breast cancer: enemy or ally?. Biosci Rep 2016; 36 (03) e00352
    CrossrefPubMedSuche in Google Scholar
  • 17 Lung DK, Reese RM, Alarid ET. Intrinsic and extrinsic factors governing the transcriptional regulation of ESR1. Horm Cancer 2020; 11 (3–4): 129-147
    CrossrefPubMedSuche in Google Scholar
  • 18 Dahm AE, Eilertsen AL, Goeman J. et al. A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women. Thromb Res 2012; 130 (01) 45-51
    CrossrefPubMedSuche in Google Scholar
  • 19 Andresen MS, Ali HO, Myklebust CF. et al. Estrogen induced expression of tissue factor pathway inhibitor-2 in MCF7 cells involves lysine-specific demethylase 1. Mol Cell Endocrinol 2017; 443: 80-88
    CrossrefPubMedSuche in Google Scholar
  • 20 Farré D, Roset R, Huerta M. et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res 2003; 31 (13) 3651-3653
    CrossrefPubMedSuche in Google Scholar
  • 21 Messeguer X, Escudero R, Farré D, Núñez O, Martínez J, Albà MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002; 18 (02) 333-334
    CrossrefPubMedSuche in Google Scholar
  • 22 Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 2018; 8 (01) 9227
    CrossrefPubMedSuche in Google Scholar
  • 23 Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J 2021; 19: 4101-4109
    CrossrefPubMedSuche in Google Scholar
  • 24 Nathan MR, Schmid P. A review of fulvestrant in breast cancer. Oncol Ther 2017; 5 (01) 17-29
    CrossrefPubMedSuche in Google Scholar
  • 25 Sharma BK, Flick MJ, Palumbo JS. Cancer-associated thrombosis: a two-way street. Semin Thromb Hemost 2019; 45 (06) 559-568
    Thieme ConnectPubMedSuche in Google Scholar
  • 26 Gran OV, Smith EN, Brækkan SK. et al. Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica 2016; 101 (09) 1046-1053
    CrossrefPubMedSuche in Google Scholar
  • 27 Kurozumi S, Matsumoto H, Kurosumi M. et al. Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. Oncol Lett 2019; 17 (03) 2647-2656
    PubMedSuche in Google Scholar
  • 28 Ochsner SA, Abraham D, Martin K. et al. The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathways. Sci Data 2019; 6 (01) 252
    CrossrefPubMedSuche in Google Scholar
  • 29 Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 2006; 147 (10) 4831-4842
    CrossrefPubMedSuche in Google Scholar
  • 30 Gong P, Madak-Erdogan Z, Li J. et al. Transcriptomic analysis identifies gene networks regulated by estrogen receptor α (ERα) and ERβ that control distinct effects of different botanical estrogens. Nucl Recept Signal 2014; 12: e001
    CrossrefPubMedSuche in Google Scholar
  • 31 Ali HO, Stavik B, Myklebust CF. et al. Oestrogens downregulate tissue factor pathway inhibitor through oestrogen response elements in the 5′-flanking region. PLoS One 2016; 11 (03) e0152114
    CrossrefPubMedSuche in Google Scholar
  • 32 Mandal S, Davie JR. Estrogen regulated expression of the p21 Waf1/Cip1 gene in estrogen receptor positive human breast cancer cells. J Cell Physiol 2010; 224 (01) 28-32
    CrossrefPubMedSuche in Google Scholar
  • 33 Anderson I, Gorski J. Estrogen receptor alpha interaction with estrogen response element half-sites from the rat prolactin gene. Biochemistry 2000; 39 (13) 3842-3847
    CrossrefPubMedSuche in Google Scholar
  • 34 Platet N, Cunat S, Chalbos D, Rochefort H, Garcia M. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol 2000; 14 (07) 999-1009
    CrossrefPubMedSuche in Google Scholar
  • 35 Ma H, Gollahon LS. ERα mediates estrogen-induced expression of the breast cancer metastasis suppressor gene BRMS1. Int J Mol Sci 2016; 17 (02) E158
    CrossrefPubMedSuche in Google Scholar
  • 36 Liu Y, Liao XW, Qin YZ, Mo XW, Luo SS. Identification of F5 as a prognostic biomarker in patients with gastric cancer. BioMed Res Int 2020; 2020: 9280841
    PubMedSuche in Google Scholar
  • 37 Cotreau MM, Chennathukuzhi VM, Harris HA. et al. A study of 17beta-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy. Maturitas 2007; 58 (04) 366-376
    CrossrefPubMedSuche in Google Scholar
  • 38 Movérare S, Skrtic S, Lindberg MK, Dahlman-Wright K, Ohlsson C. Estrogen increases coagulation factor V mRNA levels via both estrogen receptor-alpha and -beta in murine bone marrow/bone. Eur J Endocrinol 2004; 151 (02) 259-263
    CrossrefPubMedSuche in Google Scholar